I’ve been following Sagimet Biosciences Inc. (NASDAQ: SGMT ) since April of last year. Since then, they’ve continued working on their fatty acid synthase [FASN] inhibitors to treat conditions related to excessive fatty acid palmitate production. In particular, their main value driver is Denifanstat, andMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio U ...